Glass articles with low-friction coatings
Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body comprising a first surface and a second surface opposite the first surface. The glass body may be a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. In embodiments, the low-friction coating may be a fluoropolymer.
1. A coated pharmaceutical package comprising:
a glass body comprising a first surface and a second surface opposite the first surface, wherein the glass body is a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container; and
a low-friction coating positioned on at least a portion of the first surface of the glass body, the low-friction coating comprising a silsesquioxane-based polymer, wherein the low-friction coating comprises an outer surface, and the outer surface comprises the silsesquioxane-based polymer, wherein the coated pharmaceutical package is thermally stable at a temperature of at least about 260° C. for 30 minutes.
2. The coated pharmaceutical package of claim 1 , wherein the low-friction coating has a coefficient of friction of less than or equal to 0.6.
3. The coated pharmaceutical package of claim 1 , wherein a thickness of the low friction coating is less than or equal to 1 μm.
4. The coated pharmaceutical package of claim 1 , wherein a thickness of the low friction coating is less than or equal to 100 nm.
5. The coated pharmaceutical package of claim 1 , wherein a retained strength of the pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to an elevated temperature of 260° C. for 30 minutes and abrasion under a 30 N load.
6. The coated pharmaceutical package of claim 1 , wherein the portion of the exterior surface of the coated pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated borosilicate glass pharmaceutical package in a vial-on-vial testing jig under a normal load of 30 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.
7. A coated pharmaceutical package comprising:
a glass body comprising a first surface and a second surface opposite the first surface, wherein the glass body is a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container; and
a low-friction coating positioned on at least a portion of the first surface of the glass body, the low-friction coating comprising a silicone resin, and wherein at least a portion of the low-friction coating is in direct contact with the glass body;
wherein a thickness of the low friction coating is less than or equal to 1 μm, and wherein the coated pharmaceutical package is thermally stable at a temperature of at least about 260° C. for 30 minutes.
8. The coated pharmaceutical package of claim 7 , wherein the low-friction coating comprises:
a coupling agent layer positioned on the first surface of the glass body; and
a polymer layer positioned over the coupling agent layer, the polymer layer comprising the silicone resin.
9. The coated pharmaceutical package of claim 8 , wherein the coupling agent layer comprises a silsesquioxane.
10. The coated pharmaceutical package of claim 7 , wherein the low-friction coating has a coefficient of friction of less than or equal to 0.6.
11. The coated pharmaceutical package of claim 7 , wherein a thickness of the low friction coating is less than or equal to 100 nm.
12. The coated pharmaceutical package of claim 7 , wherein a retained strength of the pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to an elevated temperature of 260° C. for 30 minutes and abrasion under a 30 N load.
13. The coated pharmaceutical package of claim 7 , wherein the portion of the exterior surface of the coated pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated borosilicate glass pharmaceutical package in a vial-on-vial testing jig under a normal load of 30 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.
14. A coated pharmaceutical package comprising:
a glass body comprising a first surface and a second surface opposite the first surface, wherein the glass body is a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container; and
a low-friction coating positioned on at least a portion of the first surface of the glass body, the low-friction coating comprising a polymer selected from the group consisting of polyimides, silsesquioxane-based polymers, and silicone resins;
wherein the coated pharmaceutical package is thermally stable at a temperature of at least about 260° C. for 30 minutes, and wherein the low-friction coating has a coefficient of friction of less than or equal to 0.6, and wherein a thickness of the low friction coating is less than or equal to 1 μm.
15. The coated pharmaceutical package of claim 14 , wherein the low-friction coating comprises:
a coupling agent layer positioned on the first surface of the glass body; and
a polymer layer positioned over the coupling agent layer, the polymer layer comprising the polymer.
16. The coated pharmaceutical package of claim 15 , wherein the coupling agent layer comprises a silsesquioxane.
17. The coated pharmaceutical package of claim 14 , wherein a thickness of the low friction coating is less than or equal to 100 nm.
18. The coated pharmaceutical package of claim 14 , wherein a retained strength of the pharmaceutical package in horizontal compression does not decrease by more than about 20% after exposure to an elevated temperature of 260° C. for 30 minutes and abrasion under a 30 N load.
19. The coated pharmaceutical package of claim 14 , wherein the portion of the exterior surface of the coated pharmaceutical package with the low-friction coating contains less than 6 glass checks per 5 mm length when abraded along a length of about 20 mm with a second coated borosilicate glass pharmaceutical package in a vial-on-vial testing jig under a normal load of 30 N and after exposing the coated glass pharmaceutical package and the second coated glass pharmaceutical package to a temperature of at least about 260° C. for 30 minutes.
20. The coated pharmaceutical package of claim 14 , wherein the low-friction coating comprises silsesquioxane-based polymers.
21. The coated pharmaceutical package of claim 14 , wherein the low-friction coating comprises silicone resins.